Related Experiment Video

Updated: Aug 12, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Luteolin and neurodegenerative disease modulation: linking molecular mechanisms, neurotransmission, and

Shivani Chib1, Shaurabh Shukla1,2, Kajal Sharma1

  • 1Department of Pharmacology, Central University of Punjab, Bathinda, India.

Nutritional Neuroscience
|August 11, 2026
PubMed

Insights

Luteolin, a plant-derived flavonoid, shows potential for treating neurodegenerative diseases by targeting multiple pathways. This review explores its neuroprotective effects and therapeutic feasibility for conditions like Alzheimer's and Parkinson's disease.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Neurodegenerative diseases involve complex mechanisms like oxidative stress, neuroinflammation, and synaptic dysfunction.
  • Current treatments often target single pathways, necessitating agents with multi-target capabilities.
  • Luteolin, a dietary flavonoid, exhibits diverse biological activities relevant to neuronal health.

Purpose of the Study:

  • To provide an integrated review of luteolin's neuroprotective mechanisms in neurodegenerative disorders.
  • To examine luteolin's role in modulating interconnected signaling networks, including neuromodulation and neuroimmune regulation.
  • To assess the therapeutic potential of luteolin by considering its pharmacokinetics, metabolites, and delivery strategies.

Main Methods:

  • Literature review synthesizing studies on luteolin's effects in neurodegenerative disease models.
  • Analysis of signaling pathway convergence and cross-talk influenced by luteolin.
  • Examination of pharmacokinetic data and emerging delivery systems for luteolin.

Main Results:

  • Luteolin demonstrates pleiotropic actions, orchestrating signaling networks to preserve neuronal integrity.
  • Evidence suggests luteolin offers system-level neuroprotection across models of Alzheimer's and Parkinson's disease.
  • Pharmacokinetic and delivery considerations are being explored to enhance luteolin's efficacy.

Conclusions:

  • Luteolin presents a promising therapeutic candidate for neurodegenerative diseases due to its multi-target neuroprotective effects.
  • Understanding luteolin's integrated molecular signaling provides a refined perspective on its role in disease modulation.
  • Further research into luteolin's delivery and metabolism can optimize its clinical application.
Keywords:
Alzheimer’s diseaseNeurodegenerationParkinson’s diseaseanti-oxidantflavonoidluteolinneuroprotectionpharmacokinetics

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.